These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 7729895)

  • 1. Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins.
    von Specht BU; Knapp B; Muth G; Bröker M; Hungerer KD; Diehl KD; Massarrat K; Seemann A; Domdey H
    Infect Immun; 1995 May; 63(5):1855-62. PubMed ID: 7729895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Production of hybrid protein OprF-OprL of Pseudomonas aeruginosa].
    Kaloshin AA; Mikhaĭlova NA; Leonova EI
    Zh Mikrobiol Epidemiol Immunobiol; 2012; (3):35-43. PubMed ID: 22830272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa.
    Hassan R; El-Naggar W; Abd El-Aziz AM; Shaaban M; Kenawy HI; Ali YM
    J Microbiol Immunol Infect; 2018 Jun; 51(3):312-320. PubMed ID: 28291719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa.
    Zhang M; Sun C; Gu J; Yan X; Wang B; Cui Z; Sun X; Tong C; Feng X; Lei L; Han W
    Microbiol Immunol; 2015 Sep; 59(9):533-44. PubMed ID: 26249788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A hybrid outer membrane protein antigen for vaccination against Pseudomonas aeruginosa.
    Gabelsberger J; Knapp B; Bauersachs S; Enz UI; von Specht BU; Domdey H
    Behring Inst Mitt; 1997 Feb; (98):302-14. PubMed ID: 9382754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
    von Specht BU; Domdey H; Schödel F; Blum B; Lücking C; Knapp B; Muth G; Hungerer KD; Bröker M
    Behring Inst Mitt; 1994 Dec; (95):85-96. PubMed ID: 7538752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.
    Weimer ET; Lu H; Kock ND; Wozniak DJ; Mizel SB
    Infect Immun; 2009 Jun; 77(6):2356-66. PubMed ID: 19349426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.
    Westritschnig K; Hochreiter R; Wallner G; Firbas C; Schwameis M; Jilma B
    Hum Vaccin Immunother; 2014; 10(1):170-83. PubMed ID: 24064511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
    von Specht B; Knapp B; Hungerer K; Lücking C; Schmitt A; Domdey H
    J Biotechnol; 1996 Jan; 44(1-3):145-53. PubMed ID: 8717398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa.
    Weimer ET; Ervin SE; Wozniak DJ; Mizel SB
    Vaccine; 2009 Nov; 27(48):6762-9. PubMed ID: 19744586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Construction of recombinant Bb(pGEX-OprF-I) vaccine of Pseudomonas aeruginosa and its protection elicited in mice].
    Liang C; Li W
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Jul; 35(7):589-594. PubMed ID: 31537242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli.
    Finke M; Duchêne M; Eckhardt A; Domdey H; von Specht BU
    Infect Immun; 1990 Jul; 58(7):2241-4. PubMed ID: 2114360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients.
    Mansouri E; Blome-Eberwein S; Gabelsberger J; Germann G; von Specht BU
    FEMS Immunol Med Microbiol; 2003 Jul; 37(2-3):161-6. PubMed ID: 12832120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection of immunosuppressed mice against infection with Pseudomonas aeruginosa by recombinant P. aeruginosa lipoprotein I and lipoprotein I-specific monoclonal antibodies.
    Finke M; Muth G; Reichhelm T; Thoma M; Duchêne M; Hungerer KD; Domdey H; von Specht BU
    Infect Immun; 1991 Apr; 59(4):1251-4. PubMed ID: 1706316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers.
    Mansouri E; Gabelsberger J; Knapp B; Hundt E; Lenz U; Hungerer KD; Gilleland HE; Staczek J; Domdey H; von Specht BU
    Infect Immun; 1999 Mar; 67(3):1461-70. PubMed ID: 10024596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of the protective efficacy of an oprF DNA vaccine against Pseudomonas aeruginosa.
    Price BM; Barten Legutki J; Galloway DR; von Specht BU; Gilleland LB; Gilleland HE; Staczek J
    FEMS Immunol Med Microbiol; 2002 Jun; 33(2):89-99. PubMed ID: 12052563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mannose-modified chitosan microspheres enhance OprF-OprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity.
    Cui Z; Han D; Sun X; Zhang M; Feng X; Sun C; Gu J; Tong C; Lei L; Han W
    Appl Microbiol Biotechnol; 2015 Jan; 99(2):667-80. PubMed ID: 25381907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa.
    Arnold H; Bumann D; Felies M; Gewecke B; Sörensen M; Gessner JE; Freihorst J; von Specht BU; Baumann U
    Infect Immun; 2004 Nov; 72(11):6546-53. PubMed ID: 15501786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant N-terminal outer membrane porin (OprF) of Pseudomonas aeruginosa is a promising vaccine candidate against both P. aeruginosa and some strains of Acinetobacter baumannii.
    Bahey-El-Din M; Mohamed SA; Sheweita SA; Haroun M; Zaghloul TI
    Int J Med Microbiol; 2020 Apr; 310(3):151415. PubMed ID: 32156509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of properties of Pseudomonas aeruginosa recombinant outer membrane protein F (OprF)].
    Zlygostev SA; Gataullin AG; Kaloshin AA; Mikhaĭlova NA; Zverev VV
    Zh Mikrobiol Epidemiol Immunobiol; 2006; (7):43-7. PubMed ID: 17297879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.